MAP2K7 and melanoma: Another study demonstrates that the combination of a BRAF inhibitor and MEK inhibitor activates caspase-3 GSDME-mediated pyroptosis in melanoma, leading to increased immune response and tumor suppression in melanoma-bearing mice (171).